Alpha Cognition Inc. (ACOG)
| Market Cap | 192.52M +36.6% |
| Revenue (ttm) | 15.26M +232.7% |
| Net Income | -21.01M |
| EPS | -1.05 |
| Shares Out | 21.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,875 |
| Open | 8.88 |
| Previous Close | 8.85 |
| Day's Range | 8.77 - 9.21 |
| 52-Week Range | 4.50 - 10.14 |
| Beta | 2.24 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+103.62%) |
| Earnings Date | Aug 13, 2026 |
About ACOG
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impa... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ACOG stock is "Strong Buy." The 12-month stock price target is $18.0, which is an increase of 103.62% from the latest price.
News
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeu...
Alpha Cognition initiated with a Buy at B. Riley
B. Riley analyst William Wood last night initiated coverage of Alpha Cognition (ACOG) with a Buy rating and $21 price target Alpha is a commercial-stage specialty pharma company built around…
Alpha Cognition initiated with a Buy at B. Riley
B. Riley initiated coverage of Alpha Cognition (ACOG) with a Buy rating and $21 price target
Alpha Cognition price target raised to $20 from $18 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Alpha Cognition (ACOG) to $20 from $18 and keeps a Buy rating on the shares. The company’s “solid” sales…
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26
Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's 2Q2...
Alpha Cognition reports Q2 EPS (40c), consensus (39c)
Reports Q2 revenue $6M, consensus $6.11M. “We are pleased with the continued commercial adoption of ZUNVEYL during the second quarter,” said Michael McFadden, Chief Executive Officer of Alpha Cognitio...
Alpha Cognition price target raised to $17 from $14 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Alpha Cognition (ACOG) to $17 from $14 and keeps a Buy rating on the shares after strong Q2 results. Management noted encouraging momentum…
Alpha Cognition Earnings Call Transcript: Q2 2026
Q2 2026 saw robust sequential growth for ZUNVEYL, with net product revenue up 71% and strong adoption in long-term care. Operating expenses were reduced, and the company remains on track for 2027 profitability, despite slower-than-expected payer access.
Alpha Cognition Earnings release: Q2 2026
Alpha Cognition released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Alpha Cognition Quarterly report: Q2 2026
Alpha Cognition has published its Q2 2026 quarterly earnings report on August 13, 2026.
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for d...
Alpha Cognition Slides: Corporate presentation
Alpha Cognition has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Alpha Cognition Inc trading resumes
10:05 EDT Alpha Cognition (ACOG) Inc trading resumes
Alpha Cognition Inc trading halted, volatility trading pause
10:00 EDT Alpha Cognition (ACOG) Inc trading halted, volatility trading pause
Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announce...
Alpha Cognition announces EPO granted patent covering benzgalantamine
Alpha Cognition (ACOG) announced that the European Patent Office, EPO, has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the…
Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer's Disease
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeut...
Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for ...
Alpha Cognition initiated with an Outperform at Raymond James
Raymond James analyst Ryan Deschner initiated coverage of Alpha Cognition (ACOG) with an Outperform rating and $20 price target Alpha Cognition markets Zunveyl, a prodrug of FDA-approved galantamine, ...
Alpha Cognition appoints Robert Wills as chairman of the board
Alpha Cognition (ACOG) announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years…
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for ...
Alpha Cognition announces enrollment of first patient in Resolve
Alpha Cognition (ACOG) announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience ...
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (ACOG: NASDAQ) (“Alpha Cognition” or the “Company”), a biopharmaceutical company dedicated to developing innovati...
Alpha Cognition reports results from Beacon real-world study of Zunevyl
Alpha Cognition (ACOG) announced the top-line results from its Beacon real-world study evaluating provider-reported cognitive, behavioral, functional, and tolerability outcomes among long-term care re...
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's Disease
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeu...